the aid library

LIST OPTIONS

Filter

3152

Assessing the impact of Covid-19 on older people in the African Region

World Health Organization WHO, Regional Office of Africa (2022) C_WHO

A study conducted by the World Health Organisation Regional Office for Africa. The COVID-19 pandemic has had a significant impact on older persons both globally and in the African region. Although overall the region’s population is younger relative to many other world regions, the WHO AFRO region ... more

Download (110)

View PDF (166)

Facility based integrated management of neonatal and childhood illness (F-IMNCI) - Participants manual

Ministry of Health and Family Welfare Government of India; WHO; UNICEF (2009) C_WHO

Download (115)

View PDF (147)

Prevention and control of noncommunicable diseases in Kyrgyzstan: the case for investment

World Health Organization WHO, Regional Office of Europe (2017) C_WHO

Noncommunicable diseases (‎NCDs)‎ such as cancer, cardiovascular diseases, diabetes and chronic respiratory diseases and their risk factors are an increasing public health and development challenge in Kyrgyzstan. This report provides evidence through three analyses that NCDs reduce economic outp... more

Download (316)

View PDF (296)

Guidelines for the clinical management of severe illness from influenza virus infections

World Health Organization WHO (2022) C_WHO

Exploring the Intersection of Sanitation, Hygiene, Water, and Health in Pastoralist Communities in Northern Tanzania

Barasa, V.; Waldman, L. IDS (2022) CC

This paper explores access to water, sanitation, and health in pastoral communities in northern Tanzania. It argues that the concept of gender, used on its own, is not enough to understand the complexities of sanitation, hygiene, water, and health. It explores pastoralists’ views and perspectives ... more

Download (152)

View PDF (225)

Public health and climate change adaptation policies in the European Union

World Health Organization WHO (2017) C_WHO

Download (92)

View PDF (136)

Prevalence of noncommunicable disease risk factors in the Republic of Moldova: STEPS 2013

World Health Organization WHO, Regional Office of Europe (2014) CC

Survey

Framework for collaborative action on tuberculosis and comorbidities

World Health Organization WHO (2022) C_WHO

Addressing comorbidities and risk factors for TB is a crucial component of Pillar one of the End TB Strategy, which focuses on integrated patient-centred care and prevention, including action on TB and comorbidities. The Framework for collaborative action on TB and comorbidities aims to support coun... more

Download (185)

View PDF (197)

Questions and answers on the prevention and control of alcohol-related harm

World Health Organization, Regional Office for the Western Pacific (2019) C_WHO

The "Questions and Answers on Prevention and control of Alcohol related harm" has been developed by WHO country office in Viet Nam with technical contribution from national and international experts in the field. This publication provides scientific evidences on harms of alcohol use to the health of... more

Download (339)

View PDF (230)

Guidelines for the Clinical Diagnosis and Treatment of Dengue, Chikungunya, and Zika

Pan American Health Organisation PAHO (2022) C_WHO

Evidence-based guidelines are one of the most useful tools for improving public health and clinical practice. Their purpose is to formulate interventions based on strong evidence of efficacy, avoid unnecessary risks, use resources efficiently, reduce clinical variability and, in essence, improve hea... more

Download (177)

View PDF (213)

Human and dog rabies prevention and control

World Health Organization WHO; Bill & Melinda Gates Foundation (2009) C_WHO

Report of the WHO/Bill & Melinda Gates Foundation Consultation. The Consultation was organized back-to-back with the first annual meeting of the International Coordinating Group of the BMGF-funded project for human and dog rabies elimination in developing countries, held at WHO headquarters, Geneva,... more

External Link

Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever -Revised and expanded edition

World Health Organization WHO Regional Office for South-East Asia WHO Regional Office for South-East Asia (2011) CC

Revised and expanded version of the Guidelines

External Link

Report of the first WHO stakeholders meeting on rhodesiense human African trypanosomiasis Geneva, 20–22 October 2014

World Health Organization WHO (2014) C_WHO

The objectives of the meeting were: 1. To update the current status of the disease transmission, country capacities and plans for tackling the disease. 2. To understand the epidemiology including disease distribution and risk, the models for estimating under-detection, the geographical variati... more

External Link

A national survey of public awareness of antimicrobial resistance in Nigeria

Chukwu, E., Oladele, D., Awoderu, O. et al. Antimicrobial Resistance & Infection Control (2020) CC

Background: One of the objectives of the Global Action Plan by the World Health Organization (WHO) to contain antimicrobial resistance (AMR), is to improve global awareness through effective communication and education. Comprehensive information on the level of awareness of AMR among Nigerian public... more

External Link

Normes et recommandations techniques minimales pour les soins de santé reproductive et de santé de la mère, du nouveau-né et de l’enfant pour les équipes médicales d’urgence

World Health Organization WHO; Institutional research information system iris (2021) C_WHO

Organisation mondiale de la Santé. (‎2022)‎. Normes et recommandations techniques minimales pour les soins de santé reproductive et de santé de la mère, du nouveau-né et de l’enfant pour les équipes médicales d’urgence. Organisation mondiale de la Santé.

Download (287)

View PDF (345)

Dementia in Latin America and the Caribbean: Prevalence, Incidence, Impact, and Trends over Time

World Health Organisation (WHO) (2023) C_WHO

The chapter Dementia in Latin America and the Caribbean: Prevalence, Incidence, Impact, and Trends over Time, is part of the publication series titled “Decade of Healthy Aging: situation and challenges”. This document aims to provide an outline of the current situation in Latin America and the C... more

Download (181)

View PDF (305)

Multi-country outbreak of cholera, External situation report #4 - 6 July 2023

World Health Organisation (WHO) (2023) C_WHO

Since the last situation report on the multi-country outbreak of cholera was published on 1 June 2023 (covering data reported until 15 of May), no new country reported a cholera outbreak. In total, 24 countries have reported cases since the beginning of 2023. The WHO African Region remains the most ... more

Download (267)

View PDF (338)

Red and processed meat in the context of health and the environment: many shades of red and green: information brief

World Health Organisation (WHO) (2023) C_WHO

There is growing international consensus that food systems transformation is important to address the challenges of malnutrition in all its forms, the burden of noncommunicable diseases (NCDs), environmental sustainability, increasing inequality and ensuring the welfare of workers and animals. In li... more

Download (182)

View PDF (153)

Healthy diet metrics: a suitability assessment of indicators for global and national monitoring purposes

World Health Organisation (WHO) (2023) C_WHO

Diets are changing everywhere, and the burden of disease associated with unhealthy diets is a worldwide concern. Measurement and monitoring of diets across countries and population groups is critical. However, there are no harmonized metrics for tracking how the healthfulness of diets around the wor... more

Download (286)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more